A single dose, 2-period, 2-treatment, 2-sequence crossover bioequivalency study of novel levetiracetam extended release 1500 mg tablets under non fasting conditions.
Latest Information Update: 05 May 2017
At a glance
- Drugs Levetiracetam (Primary)
- Indications Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- 05 May 2017 New trial record
- 28 Apr 2017 Results assessing bioequivalence using patient data from this and other two trials (see CTPs 284433 and 284436), presented at the 69th Annual Meeting of the American Academy of Neurology